Marc Gagnon

USPTO Granted Patents = 14 (Patent Applications = 3)

CIPO Patents = 3

EPO Patents = 10 (Patent Applications = 6)

Average Co-Inventor Count = 4.2

ph-index = 5

Forward Citations = 49(Granted Patents)

Location History:

Montreal, CA (2007 - 2023)
Ville Saint-Laurent, CA (2017 - 2024)

Company Filing History:

7 out of 3,684

Bristol-myers Squibb Compnay

patents

6 out of 183

Universitéde Montreal

patents

3 out of 212

Merck Frosst Canada, Inc.

patents

4. 1 out of 76

Merck Frosst Canada & Co.

patents

5. 1 out of 2,405

Merck Sharp + Dohme Corp.

patents

6. 2 out of 832,843

Other

patents

where one patent can have more than one assignee

Years Active: 2007-2024

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12084452 - Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation (2024-09-10),

2. 11559160 - Automated immersion apparatus and method for cooking meals (2023-01-24),

3. 10822343 - Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation (2020-11-03),

4. 10537198 - Automated immersion apparatus and method for cooking meals (2020-01-21),

5. 10428077 - Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation (2019-10-01),

6. 10238638 - Benzothiazole and benzothiophene compounds (2019-03-26),

7. 10047103 - Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation (2018-08-14),

8. 9862730 - Imidazothiadiazole derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation (2018-01-09),

9. 9688695 - Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation (2017-06-27),

10. 7960409 - Pharmaceutical phenylquinoline and chromen-2-one triazole compounds (2011-06-14),

11. 7943649 - 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors (2011-05-17),

12. 7553973 - Pharmaceutical compounds (2009-06-30),

13. 7442716 - 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors (2008-10-28),

14. 7279478 - Cathepsin cysteine protease inhibitors (2007-10-09),

Title: Marc Gagnon - Innovative Inventor from Montreal, CA

Introduction: Marc Gagnon is a renowned inventor hailing from Montreal, Canada, known for his groundbreaking contributions to various fields.

Latest Patents: Marc Gagnon holds several patents in the areas of renewable energy technologies, medical devices, and consumer electronics, showcasing his diverse range of expertise.

Career Highlights: With over two decades of experience in the innovation industry, Marc Gagnon has successfully brought numerous inventions from concept to market, revolutionizing the way we live and work.

Collaborations: Throughout his career, Marc Gagnon has collaborated with leading research institutions, universities, and companies worldwide, fostering a culture of innovation and excellence.

Conclusion: Marc Gagnon's passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors and entrepreneurs globally.

This text is generated by artificial intelligence and may not be accurate.